A Dose-response Study of the Effects of Exendin-9,39 on Glucose Metabolism, Glucagon and Insulin Secretion and on Insulin Action.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Adrian Vella
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Insulin Secretion
研究概览
简要总结
Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actions at the receptor. It is possible that the supraphysiologic concentrations of Exendin may have effects of its own. To examine the effect of Exendin on glucose metabolism the investigators propose a dose-response study to determine whether the compound has effects in a dose-dependent fashion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Saline
干预措施: saline infusion (Drug)
GLP-1-(9,36)-amide
干预措施: GLP-1-9,36 infusion (Drug)
Exendin-9,39 @30pmol/kg/min
干预措施: Exendin-9,39 at low dose (Drug)
Exendin-9,39 @300pmol/kg/min
干预措施: Exendin-9,39 at high dose (Drug)
结局指标
主要结局
Insulin Secretion
时间窗: over 360 minutes of study
次要结局
- glucagon secretion(over 360 minutes of study)